Abstract
BRCA mutation-associated breast cancer differs from sporadic breast cancer as studies show that they have higher risk of breast and ovarian cancer and also has differential sensitivity to chemotherapeutic agents. It is an accepted general opinion that breast cancer outcome for BRCA1/2 mutation carriers is at least as good as for non-carriers. On the other hand, we know that BRCA1 and BRCA2 mutation carriers have a lifetime risk of breast cancer in the ranges 47-66% and 40-57%, respectively. Additionally, women with BRCA mutation-associated breast cancer also have an elevated risk of other or secondary malignancies. Therefore, identification of those who might have a mutation is important so that genetic counseling, testing, screening, and prevention strategies can be applied. This article reviews the sensitivity of BRCA-defective breast cancer cell lines to platinum cytotoxic compounds, poly (ADP-ribose) polymerase inhibitors, and endocrine therapy is reviewed.
Original language | English (US) |
---|---|
Title of host publication | Managing BRCA Mutation Carriers |
Publisher | Springer International Publishing |
Pages | 135-150 |
Number of pages | 16 |
ISBN (Electronic) | 9783319591988 |
ISBN (Print) | 9783319591971 |
DOIs | |
State | Published - Jul 13 2017 |
Keywords
- BRCA1
- BRCA2
- Breast cancer
- Hereditary breast cancer
- Platinums
- Prevention
- Prophylactic mastectomy
- Prophylactic oophorectomy PARP inhibitors
- Risk models
ASJC Scopus subject areas
- General Medicine
- General Biochemistry, Genetics and Molecular Biology